Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

March 14, 2013

Stuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.

March 11, 2013

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, describes a study looking at sorafenib plus doxorubicin compared with doxorubicin alone in patients with advanced hepatocellular carcinoma.

March 06, 2013

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

February 11, 2013

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses the promising results and future investigation of MET inhibition in hepatocellular carcinoma using cabozantinib and tivantinib.

January 04, 2013

Mark G. Kris, MD, offers insight into NSCLC related topics, including emerging therapeutic targets, the optimal application of TKIs, strategies for patients with poor performance status, maintenance therapies, and the treatment pipeline.

January 04, 2013

Treating estrogen receptor–positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

December 22, 2012

Although the association between VEGF and ovarian cancer has been known for quite some time, researchers are still struggling to use drugs that inhibit VEGF and angiogenesis in patients with the disease.

March 14, 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Discusses what Separates MSKCC From Other Top Cancer Centers Worldwide